ovarian neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our study indicated that Chk2 and p27 were vital anticancer targets of TF3 and provided more evidence that TF3 might be a potent agent to be applied as adjuvant treatment for ovarian cancer.
|
30769778 |
2019 |
ovarian neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We analyzed germline CHEK2 variants in 1,928 high-risk Czech breast/ovarian cancer (BC/OC) patients and 3,360 population-matched controls (PMCs).
|
31050813 |
2019 |
ovarian neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In this study, we have genotyped 68 MBC patients for the known breast or ovarian cancer associated mutations in the Finnish population in CHEK2, PALB2, RAD51C, RAD51D, and FANCM genes.
|
28874143 |
2017 |
ovarian neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
The recent approval of three different PARP inhibitors for the treatment of ovarian cancer provides the impetus for further developing targeted inhibitors of many of the kinases involved in the DDR, including inhibitors of ATR, ATM, CHEK1, CHEK2, DNAPK and WEE1.
|
28984489 |
2017 |
ovarian neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
Chk2-depleted ovarian cancer cell lines have diminished platinum sensitivity, suggesting that Chk2 should not be considered a therapeutic target along with platinum-based treatment in HGSOC patients.
|
24657486 |
2014 |
ovarian neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that CHEK2 mutations may not contribute significantly to breast/ovarian cancer risk in Pakistani women.
|
23806170 |
2013 |
ovarian neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We discussed the potential application of CHEK2 variants in the evaluation of breast and ovarian cancer predisposition.
|
21120647 |
2011 |
ovarian neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that CHEK2 variants may predispose to a range of ovarian tumor types of low malignant potential, but not to aggressive cancers.
|
16828850 |
2006 |
ovarian neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
Twenty-three percent of ovarian tumors were negative for Chk2 protein by immunohistochemistry, but there was no significant correlation between LOH across the CHEK2 locus and intensity of Chk2 staining (P = 0.12).
|
17145815 |
2006 |
ovarian neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Between 2002-2005, probands from 300 US families with 4 or more cases of breast or ovarian cancer but with negative (wild-type) commercial genetic test results for BRCA1 and BRCA2 were screened by multiple DNA-based and RNA-based methods to detect genomic rearrangements in BRCA1 and BRCA2 and germline mutations of all classes in CHEK2, TP53, and PTEN.
|
16551709 |
2006 |
ovarian neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that variations in CHEK2 do not make a significant contribution to the pathogenesis of OvCa in the U.S. population.
|
15385111 |
2004 |
ovarian neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This is the first study from South India, on BRCA1, BRCA2 & CHEK2 (1100 del C) mutations in patients with a family history of breast and/or ovarian cancer and early onset breast/ovarian cancer, using the sensitive DHPLC approach.
|
14507240 |
2003 |
ovarian neoplasm
|
0.200 |
GeneticVariation
|
disease |
LHGDN |
This is the first study from South India, on BRCA1, BRCA2 & CHEK2 (1100 del C) mutations in patients with a family history of breast and/or ovarian cancer and early onset breast/ovarian cancer, using the sensitive DHPLC approach.
|
14507240 |
2003 |
ovarian neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors.
|
11746983 |
2002 |
ovarian neoplasm
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|
ovarian neoplasm
|
0.200 |
CausalMutation
|
disease |
CLINVAR |
|
|
|